Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Price Target at $13.75

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been given a consensus rating of “Hold” by the five research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $13.75.

A number of equities research analysts recently commented on TBPH shares. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. TD Cowen decreased their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Large investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new stake in Theravance Biopharma in the 2nd quarter valued at $986,000. Bank of Montreal Can increased its position in Theravance Biopharma by 141.0% during the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after purchasing an additional 93,702 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Theravance Biopharma by 16.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock valued at $474,000 after purchasing an additional 7,509 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Theravance Biopharma by 38.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after buying an additional 91,679 shares during the period. Finally, Marshall Wace LLP increased its stake in Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $9.52 on Thursday. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.71. The stock has a market cap of $465.72 million, a PE ratio of -9.43 and a beta of 0.25. The stock has a 50-day moving average of $8.42 and a two-hundred day moving average of $8.70.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative return on equity of 24.23% and a negative net margin of 78.18%. During the same period in the prior year, the firm posted ($0.17) EPS. As a group, sell-side analysts predict that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.